Work

Comparison of clinical and molecular characteristics of patients with acute myeloid leukemia and either TP73 or TP53 mutations

Year: 2020

Type: article

Source: Leukemia

DOI: 10.1038/s41375-020-1007-6

Authors: Alice S. Mims, Jessica Kohlschmidt, Ann-Kathrin Eisfeld, Krzysztof Mrόzek, James S. Blachly, Shelley Orwick, Dimitrios Papaioannou, Deedra Nicolet, Deepa Sampath, Richard M. Stone, Bayard L. Powell, Jonathan E. Kolitz, John C. Byrd, Clara D. Bloomfield

Institutions: The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Dana-Farber Cancer Institute, Atrium Health Wake Forest Baptist, Wake Forest Baptist Comprehensive Cancer Center, Northwell Health, Hofstra University

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: U.S. Department of Health and Human Services, European Hematology Association, National Institutes of Health, National Cancer Institute

Awards: G1249701252, Alliance Statistics and Data Management Center, G1581977058, G1713549810, G2177483498, G2350719019, Targeted Therapy for Leukemia, Experimental Therapeutics of Leukemia, G2971717161, G3032743408, Cancer and Leukemia Group B - Leukemia Correlative Sciences, G4185274752, NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care, G6029025976, G6105514657, Alliance for Clinical Trials in Oncology Operations Center, Cancer Center Support Grant

OpenAlex ID: W3046957137

FWCI: 0.27

Cites: 15

Cited by: 3

Related to: 10